Literature DB >> 6818900

Synergism between N-formimidoyl thienamycin and gentamicin or tobramycin against enterococci.

C Watanakunakorn, J C Tisone.   

Abstract

By the time-kill curve method, the combination of N-formimidoyl thienamycin and gentamicin showed synergism against 47 of 48 strains of enterococci, whereas the combination of N-formimidoyl thienamycin and tobramycin was synergistic against 46 strains.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6818900      PMCID： PMC185728          DOI： 10.1128/AAC.22.6.1082

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Penicillin combined with gentamicin or streptomycin: synergism against enterococci.

Authors:  C Watanakunakorn
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

2.  N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; N Patel
Journal:  J Antimicrob Chemother       Date:  1981-05       Impact factor: 5.790

3.  Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin.

Authors:  R C Moellering; C Wennersten; A J Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

4.  In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp.

Authors:  W K Livingston; A M Elliott; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

5.  N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.

Authors:  D Hanslo; A King; K Shannon; C Warren; I Phillips
Journal:  J Antimicrob Chemother       Date:  1981-06       Impact factor: 5.790

6.  Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci.

Authors:  C Watanakunakorn; C Bakie
Journal:  Antimicrob Agents Chemother       Date:  1973-08       Impact factor: 5.191
  6 in total
  5 in total

1.  In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin.

Authors:  E Debbia; P E Varaldo; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

Review 2.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 3.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

4.  Synergy of imipenem or penicillin G and aminoglycosides against enterococci isolated from patients with infective endocarditis.

Authors:  J A Indrelie; W R Wilson; J Y Matsumoto; J E Geraci; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

5.  [Dosage of imipenem/cilastatin].

Authors:  P M Shah
Journal:  Infection       Date:  1986       Impact factor: 3.553
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.